top of page

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

117.88 -1.75 (-1.46%)

Streaming Delayed Price Updated: 3:21 PM EDT, Mar 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins

Today 11:45 EDT

From Merck & Co., Inc.

Via Business Wire

This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks ↗

Today 6:50 EDT

The Schwab U.S. Dividend Equity ETF is increasing its allocation to healthcare dividend stocks.

Via The Motley Fool

Topics ETFs Stocks

Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

March 29, 2026

From Merck & Co., Inc.

Via Business Wire

Merck & Co. Inc. (NYSE:MRK) Offers a Steady Dividend Backed by Strong Fundamentals ↗

March 16, 2026

Via Chartmill

1 Reason Eli Lilly Stock Is Still a Buy ↗

March 28, 2026

Eli Lilly is much more than just a weight loss stock.

Via The Motley Fool

Topics Artificial Intelligence

2 Healthcare Stocks That Could Soar Over the Next 5 Years ↗

March 26, 2026

They could make important breakthroughs in their target markets.

Via The Motley Fool

MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough

March 26, 2026

The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the...

Via MarketMinute

Topics Intellectual Property

ARM Makes Its Move While Wall Street Watches the Strait ↗

March 26, 2026

Via Chartmill

The Strategic Renaissance: Why 2026 is the Year of the Takeover Tailwind

March 25, 2026

As of March 25, 2026, the global financial markets are witnessing a seismic shift in corporate strategy, marking the definitive end of the "deal winter" that chilled boardrooms for much of the early...

Via MarketMinute

Topics Artificial Intelligence Economy

The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition

March 25, 2026

On this Wednesday, March 25, 2026, the biotechnology sector has been electrified by the announcement that Merck & Co. (NYSE: MRK) will acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in an all-cash...

Via Finterra

Topics Initial Public Offering Intellectual Property World Trade

Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience

March 25, 2026

As of March 25, 2026, Merck & Co., Inc. (NYSE: MRK) stands at a pivotal crossroads in its 135-year history. Known globally as a titan of oncology and vaccines, the Rahway, New Jersey-based...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

March 25, 2026

From Terns Pharmaceuticals, Inc.

Via GlobeNewswire

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

March 25, 2026

From Merck & Co., Inc.

Via Business Wire

1 S&P 500 Stock to Target This Week and 2 We Ignore

March 24, 2026

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...

Via StockStory

Topics Stocks

Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield

March 23, 2026

Shares of pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) climbed 3.3% in early trading on Monday, March 23, 2026, after the company issued a surprisingly robust financial outlook for the fiscal...

Via MarketMinute

Topics Economy Initial Public Offering Intellectual Property

Pfizer vs Moderna: Which Pharma Stock Has More Upside? ↗

March 19, 2026

They aren't just "pandemic stocks."

Via The Motley Fool

Topics Intellectual Property

FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs

March 18, 2026

From Merck & Co., Inc.

Via Business Wire

The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms

March 18, 2026

In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

The Grand Divergence: Finance Surges as Health Care Braces for a Historic Q1 Earnings Slump

March 17, 2026

As the first quarter of 2026 draws to a close, the S&P 500 is witnessing one of the most dramatic sector performance splits in recent financial history. According to consensus estimates as of March 17,...

Via MarketMinute

Topics Earnings Economy Initial Public Offering

Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026

March 17, 2026

From Merck Sharp & Dohme

Via Business Wire

The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery

March 16, 2026

The biotech sector has found its new North Star in 2026. As of mid-March, Moderna Inc. (NASDAQ: MRNA) has shocked Wall Street with a staggering 83% year-to-date gain, catapulting it to the upper...

Via MarketMinute

Topics Artificial Intelligence Initial Public Offering Stocks

Merck & Co. Trades Ex-Dividend as Healthcare Emerges as a Volatility Hedge in 2026

March 16, 2026

Amidst a backdrop of mounting geopolitical tensions and sharp swings in the broader indices, pharmaceutical giant Merck & Co. (NYSE: MRK) officially trades ex-dividend today, March 16, 2026. Investors...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research

March 16, 2026

From Merck & Co., Inc.

Via Business Wire

1 ETF That Could Turn $100 Per Month Into $67,380 ↗

March 15, 2026

How does solid growth -- plus a 3.3% dividend yield sound?

Via The Motley Fool

Topics ETFs Economy World Trade

Flight to Quality: JPMorgan and Eli Lilly Emerge as Defensive Anchors Amid Geopolitical Storm

March 13, 2026

In a day marked by heightened global tensions and a sharp spike in energy prices, the U.S. equity markets witnessed a decisive "Great Rotation" as investors abandoned high-growth technology names in...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

The Dividend Shield: How Meta, Microsoft, Merck, and Target are Signal-Boosting Balance Sheet Strength in a Cooling 2026 Economy

March 13, 2026

As of March 13, 2026, the global financial landscape is navigating a delicate transition. Following the aggressive rate hikes of previous years and a subsequent "soft landing" throughout 2025, the U.S....

Via MarketMinute

Topics Artificial Intelligence Economy Workforce

March 13, 2026

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...

Via StockStory

BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier

March 10, 2026

In a watershed moment for the biotechnology sector, BioNTech SE (NASDAQ: BNTX) has reported its full-year 2025 financial results, signaling the definitive end of the COVID-19 vaccine gold rush and the...

Via MarketMinute

Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity

March 10, 2026

As of today, March 10, 2026, Pfizer Inc. (NYSE: PFE) stands at a pivotal crossroads in its 177-year history. After experiencing a meteoric rise during the COVID-19 pandemic followed by a sobering...

Via Finterra

Topics Economy Intellectual Property Lawsuit

2 Dow Jones Stocks to Research Further and 1 Facing Headwinds

March 09, 2026

The Dow Jones (^DJI) is home to corporate giants, but size alone doesn’t guarantee success. A few of these companies are struggling with weak fundamentals, p...

Via StockStory

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

220 S. Main St.
Colville, WA 99114

Hours: Mon.-Fri., 8 a.m.-5 p.m.

509-684-4567
editor@statesmanexaminer.com

Site by Amber S. King – Creative Design

Home
About
Contact
Submissions

bottom of page